Table 2. Clinical and histopathological findings in MM-RI patients and controls.
| MM with RI | Control | |
|---|---|---|
| SBP (mmHg) | 126.8 ± 11.6 | 124.5 ± 13.5 |
| DBP (mmHg) | 77 ± 10.6 | 75 ± 10.8 |
| Bone marrow plasma cell (%) | 43.5 ± 13.2 | – |
| Hemoglobin (g/dL) | 7.5 ± 1.1* | 13.0 ± 1.6 |
| IgG (g/L) (n = 26) | 60.19 ± 9.80* | 12.10 ± 2.61 |
| IgA (g/L) (n = 4 ) | 38.10 ± 2.72* | 2.04 ± 0.53 |
| Blood β2-microglobulin (mmol/L) | 6.7 ± 1.04* | 0.91 ± 0.23 |
| sFLC (mg/L) | 1876 ± 364* | 0.963 ± 0.32 |
| Albumin (g/dL) | 3.5 ± 0.21* | 4.1 ± 0.36 |
| Proteinuria (g/day) | 3.02 ± 0.15 | – |
| Hematuria (×104 cells/mL) | 74.13 ± 6.25 | – |
| BUN (mg/dL) | 18.5 ± 2.76* | 11.34 ± 0.83 |
| Serum Cr (mg/dL) | 1.82 ± 0.25* | 0.74 ± 0.26 |
| Serum uric acid (μmol/L) | 441.52 ± 56.08* | 334.25 ± 63.47 |
| eGFR (mL/min/1.73 m2) | 80.21 ± 7.83* | 112.67 ± 7.25 |
| Serum C3 (mg/dL) | 106.5 ± 23.91 | 108.2 ± 26.01 |
| Serum IL-2 (pg/ml) | 121.3 ± 10.74* | 23.4 ± 7.54 |
| supernatant IL-4 (pg/ml) | 326.15 ± 73.02* | 201.36 ± 90.32 |
| Serum IL-6 (pg/ml) | 49.56 ± 7.18* | 27.52 ± 6.82 |
| I/II (ISS) | 19 | – |
| III (ISS) | 11 | – |
| AI/CI (median) | 10.5 ± 2.3/3.4 ± 0.2 | – |
| Kappa (%) | 16 (84) | – |
| Lambda (%) | 3 (16) | – |
SBP, systolic blood pressure; DBP, diastolic blood pressure; AI, activity index; CI, chronicity index; *P < 0.05 compared to the control.